tp-064 Search Results


tp 064  (Tocris)
94
Tocris tp 064
Tp 064, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tp 064/product/Tocris
Average 94 stars, based on 1 article reviews
tp 064 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
tp 064  (MedChemExpress)
93
MedChemExpress tp 064
Tp 064, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tp 064/product/MedChemExpress
Average 93 stars, based on 1 article reviews
tp 064 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
carm1 inhibitors  (Tocris)
93
Tocris carm1 inhibitors
BAF complex ATPase inhibition and degradation are novel therapeutic strategies in pediatric H3K27M-glioma. A, Heat map of IC 50 values comparing small-molecule inhibitors and a degrader targeting BAF complex members, and its regulators (BRG1/BRM inhibitors: Compounds 11, 12, 14, PFI-3; <t>CARM1</t> inhibitors: CARM1 inhibitor, <t>TP064;</t> BRD9 inhibitor: I-BRD9; and BRD9 degrader: dBRD9-13) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs). B, PRISM analysis of 694 cancer cell lines representing 23 lineages (Broad Institute), treated with a BRG1/BRM inhibitor (Compound 11) at an 8-point dose curve (3-fold dilution, with a maximum of 10 μmol/L) for 5 days. The black dashed line represents the mean AUC computed over cell lines of all lineages. Cancer lineages below this line represent those sensitive to BRG1/BRM inhibition by Compound 11. C, Chemical structures of BRG1/BRM inhibitors (Compounds 11, 12, and 14) and a novel BRG1/BRM degrader (JQ-dS-4). D, Log 2 fold change (FC) of differential proteins (left) as assessed by SILAC of DMSO control (light isotope labeled) and 1 μmol/L JQ-dS-4 (heavy isotope labeled)–treated BT869 H3.3K27M-glioma neurospheres (2 days of treatment). Heat map (right) of BAF complex proteins (with encoding genes shown in parentheses) depleted upon JQ-dS-4 treatment in BT869 neurospheres. E, Immunoblot for BRG1 and BRM protein levels in BT869, HSJD-DIPG007, and SU-DIPGXIIIP* neurospheres treated with novel BRG1/BRM degraders (AU-15330 and JQ-dS-4) at indicated doses and time points. Cleaved PARP was used as a marker for apoptosis. Total H3 and GAPDH served as loading controls. F, Heat map of IC 50 values comparing two BRG1/BRM degraders (JQ-dS-4 and AU-15330) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs). G, Dose–response curves for BRG1/BRM degraders (AU-15330 and JQ-dS-4) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs).
Carm1 Inhibitors, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/carm1 inhibitors/product/Tocris
Average 93 stars, based on 1 article reviews
carm1 inhibitors - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
compound tp-008  (Takeda)
90
Takeda compound tp-008
BAF complex ATPase inhibition and degradation are novel therapeutic strategies in pediatric H3K27M-glioma. A, Heat map of IC 50 values comparing small-molecule inhibitors and a degrader targeting BAF complex members, and its regulators (BRG1/BRM inhibitors: Compounds 11, 12, 14, PFI-3; <t>CARM1</t> inhibitors: CARM1 inhibitor, <t>TP064;</t> BRD9 inhibitor: I-BRD9; and BRD9 degrader: dBRD9-13) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs). B, PRISM analysis of 694 cancer cell lines representing 23 lineages (Broad Institute), treated with a BRG1/BRM inhibitor (Compound 11) at an 8-point dose curve (3-fold dilution, with a maximum of 10 μmol/L) for 5 days. The black dashed line represents the mean AUC computed over cell lines of all lineages. Cancer lineages below this line represent those sensitive to BRG1/BRM inhibition by Compound 11. C, Chemical structures of BRG1/BRM inhibitors (Compounds 11, 12, and 14) and a novel BRG1/BRM degrader (JQ-dS-4). D, Log 2 fold change (FC) of differential proteins (left) as assessed by SILAC of DMSO control (light isotope labeled) and 1 μmol/L JQ-dS-4 (heavy isotope labeled)–treated BT869 H3.3K27M-glioma neurospheres (2 days of treatment). Heat map (right) of BAF complex proteins (with encoding genes shown in parentheses) depleted upon JQ-dS-4 treatment in BT869 neurospheres. E, Immunoblot for BRG1 and BRM protein levels in BT869, HSJD-DIPG007, and SU-DIPGXIIIP* neurospheres treated with novel BRG1/BRM degraders (AU-15330 and JQ-dS-4) at indicated doses and time points. Cleaved PARP was used as a marker for apoptosis. Total H3 and GAPDH served as loading controls. F, Heat map of IC 50 values comparing two BRG1/BRM degraders (JQ-dS-4 and AU-15330) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs). G, Dose–response curves for BRG1/BRM degraders (AU-15330 and JQ-dS-4) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs).
Compound Tp 008, supplied by Takeda, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compound tp-008/product/Takeda
Average 90 stars, based on 1 article reviews
compound tp-008 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
prmt4 inhibitor tp-064  (BioTherapeutics Inc)
90
BioTherapeutics Inc prmt4 inhibitor tp-064
BAF complex ATPase inhibition and degradation are novel therapeutic strategies in pediatric H3K27M-glioma. A, Heat map of IC 50 values comparing small-molecule inhibitors and a degrader targeting BAF complex members, and its regulators (BRG1/BRM inhibitors: Compounds 11, 12, 14, PFI-3; <t>CARM1</t> inhibitors: CARM1 inhibitor, <t>TP064;</t> BRD9 inhibitor: I-BRD9; and BRD9 degrader: dBRD9-13) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs). B, PRISM analysis of 694 cancer cell lines representing 23 lineages (Broad Institute), treated with a BRG1/BRM inhibitor (Compound 11) at an 8-point dose curve (3-fold dilution, with a maximum of 10 μmol/L) for 5 days. The black dashed line represents the mean AUC computed over cell lines of all lineages. Cancer lineages below this line represent those sensitive to BRG1/BRM inhibition by Compound 11. C, Chemical structures of BRG1/BRM inhibitors (Compounds 11, 12, and 14) and a novel BRG1/BRM degrader (JQ-dS-4). D, Log 2 fold change (FC) of differential proteins (left) as assessed by SILAC of DMSO control (light isotope labeled) and 1 μmol/L JQ-dS-4 (heavy isotope labeled)–treated BT869 H3.3K27M-glioma neurospheres (2 days of treatment). Heat map (right) of BAF complex proteins (with encoding genes shown in parentheses) depleted upon JQ-dS-4 treatment in BT869 neurospheres. E, Immunoblot for BRG1 and BRM protein levels in BT869, HSJD-DIPG007, and SU-DIPGXIIIP* neurospheres treated with novel BRG1/BRM degraders (AU-15330 and JQ-dS-4) at indicated doses and time points. Cleaved PARP was used as a marker for apoptosis. Total H3 and GAPDH served as loading controls. F, Heat map of IC 50 values comparing two BRG1/BRM degraders (JQ-dS-4 and AU-15330) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs). G, Dose–response curves for BRG1/BRM degraders (AU-15330 and JQ-dS-4) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs).
Prmt4 Inhibitor Tp 064, supplied by BioTherapeutics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prmt4 inhibitor tp-064/product/BioTherapeutics Inc
Average 90 stars, based on 1 article reviews
prmt4 inhibitor tp-064 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
tp-064 cayman chemical #20256  (Cayman Chemical)
90
Cayman Chemical tp-064 cayman chemical #20256
BAF complex ATPase inhibition and degradation are novel therapeutic strategies in pediatric H3K27M-glioma. A, Heat map of IC 50 values comparing small-molecule inhibitors and a degrader targeting BAF complex members, and its regulators (BRG1/BRM inhibitors: Compounds 11, 12, 14, PFI-3; <t>CARM1</t> inhibitors: CARM1 inhibitor, <t>TP064;</t> BRD9 inhibitor: I-BRD9; and BRD9 degrader: dBRD9-13) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs). B, PRISM analysis of 694 cancer cell lines representing 23 lineages (Broad Institute), treated with a BRG1/BRM inhibitor (Compound 11) at an 8-point dose curve (3-fold dilution, with a maximum of 10 μmol/L) for 5 days. The black dashed line represents the mean AUC computed over cell lines of all lineages. Cancer lineages below this line represent those sensitive to BRG1/BRM inhibition by Compound 11. C, Chemical structures of BRG1/BRM inhibitors (Compounds 11, 12, and 14) and a novel BRG1/BRM degrader (JQ-dS-4). D, Log 2 fold change (FC) of differential proteins (left) as assessed by SILAC of DMSO control (light isotope labeled) and 1 μmol/L JQ-dS-4 (heavy isotope labeled)–treated BT869 H3.3K27M-glioma neurospheres (2 days of treatment). Heat map (right) of BAF complex proteins (with encoding genes shown in parentheses) depleted upon JQ-dS-4 treatment in BT869 neurospheres. E, Immunoblot for BRG1 and BRM protein levels in BT869, HSJD-DIPG007, and SU-DIPGXIIIP* neurospheres treated with novel BRG1/BRM degraders (AU-15330 and JQ-dS-4) at indicated doses and time points. Cleaved PARP was used as a marker for apoptosis. Total H3 and GAPDH served as loading controls. F, Heat map of IC 50 values comparing two BRG1/BRM degraders (JQ-dS-4 and AU-15330) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs). G, Dose–response curves for BRG1/BRM degraders (AU-15330 and JQ-dS-4) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs).
Tp 064 Cayman Chemical #20256, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tp-064 cayman chemical #20256/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
tp-064 cayman chemical #20256 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


BAF complex ATPase inhibition and degradation are novel therapeutic strategies in pediatric H3K27M-glioma. A, Heat map of IC 50 values comparing small-molecule inhibitors and a degrader targeting BAF complex members, and its regulators (BRG1/BRM inhibitors: Compounds 11, 12, 14, PFI-3; CARM1 inhibitors: CARM1 inhibitor, TP064; BRD9 inhibitor: I-BRD9; and BRD9 degrader: dBRD9-13) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs). B, PRISM analysis of 694 cancer cell lines representing 23 lineages (Broad Institute), treated with a BRG1/BRM inhibitor (Compound 11) at an 8-point dose curve (3-fold dilution, with a maximum of 10 μmol/L) for 5 days. The black dashed line represents the mean AUC computed over cell lines of all lineages. Cancer lineages below this line represent those sensitive to BRG1/BRM inhibition by Compound 11. C, Chemical structures of BRG1/BRM inhibitors (Compounds 11, 12, and 14) and a novel BRG1/BRM degrader (JQ-dS-4). D, Log 2 fold change (FC) of differential proteins (left) as assessed by SILAC of DMSO control (light isotope labeled) and 1 μmol/L JQ-dS-4 (heavy isotope labeled)–treated BT869 H3.3K27M-glioma neurospheres (2 days of treatment). Heat map (right) of BAF complex proteins (with encoding genes shown in parentheses) depleted upon JQ-dS-4 treatment in BT869 neurospheres. E, Immunoblot for BRG1 and BRM protein levels in BT869, HSJD-DIPG007, and SU-DIPGXIIIP* neurospheres treated with novel BRG1/BRM degraders (AU-15330 and JQ-dS-4) at indicated doses and time points. Cleaved PARP was used as a marker for apoptosis. Total H3 and GAPDH served as loading controls. F, Heat map of IC 50 values comparing two BRG1/BRM degraders (JQ-dS-4 and AU-15330) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs). G, Dose–response curves for BRG1/BRM degraders (AU-15330 and JQ-dS-4) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs).

Journal: Cancer Discovery

Article Title: BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma

doi: 10.1158/2159-8290.CD-21-1491

Figure Lengend Snippet: BAF complex ATPase inhibition and degradation are novel therapeutic strategies in pediatric H3K27M-glioma. A, Heat map of IC 50 values comparing small-molecule inhibitors and a degrader targeting BAF complex members, and its regulators (BRG1/BRM inhibitors: Compounds 11, 12, 14, PFI-3; CARM1 inhibitors: CARM1 inhibitor, TP064; BRD9 inhibitor: I-BRD9; and BRD9 degrader: dBRD9-13) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs). B, PRISM analysis of 694 cancer cell lines representing 23 lineages (Broad Institute), treated with a BRG1/BRM inhibitor (Compound 11) at an 8-point dose curve (3-fold dilution, with a maximum of 10 μmol/L) for 5 days. The black dashed line represents the mean AUC computed over cell lines of all lineages. Cancer lineages below this line represent those sensitive to BRG1/BRM inhibition by Compound 11. C, Chemical structures of BRG1/BRM inhibitors (Compounds 11, 12, and 14) and a novel BRG1/BRM degrader (JQ-dS-4). D, Log 2 fold change (FC) of differential proteins (left) as assessed by SILAC of DMSO control (light isotope labeled) and 1 μmol/L JQ-dS-4 (heavy isotope labeled)–treated BT869 H3.3K27M-glioma neurospheres (2 days of treatment). Heat map (right) of BAF complex proteins (with encoding genes shown in parentheses) depleted upon JQ-dS-4 treatment in BT869 neurospheres. E, Immunoblot for BRG1 and BRM protein levels in BT869, HSJD-DIPG007, and SU-DIPGXIIIP* neurospheres treated with novel BRG1/BRM degraders (AU-15330 and JQ-dS-4) at indicated doses and time points. Cleaved PARP was used as a marker for apoptosis. Total H3 and GAPDH served as loading controls. F, Heat map of IC 50 values comparing two BRG1/BRM degraders (JQ-dS-4 and AU-15330) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs). G, Dose–response curves for BRG1/BRM degraders (AU-15330 and JQ-dS-4) in H3.3K27M ( n = 5), H3.1K27M ( n = 1), and H3WT ( n = 3) pediatric glioma neurosphere models and nonmalignant cell lines ( n = 2, NHA-hTERT: immortalized normal human astrocytes, and Oli Neu: immortalized normal mouse OPCs).

Article Snippet: CARM1 inhibitors (CARM1 inhibitor and TP064) were purchased from Sigma and Tocris Biosciences, respectively.

Techniques: Inhibition, Control, Labeling, Western Blot, Marker